Open AccessRosiglitazone does not improve vascular function in subjects with chronic kidney disease
Author(s) -
D. T. Chan,
Gerald F. Watts,
Ashley Irish,
Gursharan Dogra
Publication year - 2011
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfr049
Subject(s) - medicine , kidney disease , pulse wave velocity , arterial stiffness , placebo , renal function , blood pressure , rosiglitazone , c reactive protein , endocrinology , cardiology , inflammation , insulin , pathology , alternative medicine
Thiazolidinediones such as rosiglitazone (RSG) are insulin-sensitizing agents, which may improve inflammation and vascular function, and thus potentially lower cardiovascular risk in patients with chronic kidney disease (CKD). However, there is growing concern about the adverse cardiovascular effects of RSG in diabetic patients without CKD, and the data in patients with CKD remain conflicting. This study examines the effect of RSG on vascular function in patients with CKD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom